AUSTIN, Texas / May 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s First Quarter 2023 Financial Results |
Date: | Tuesday, May 9, 2023 |
Time: | 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: | 1 (888) 770-7321, Domestic |
| 1 (929) 201-7107, International |
Conference ID: | 7684785 |
Webcast: | |
A webcast replay will be available at investor.natera.com. |
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Last Trade: | US$105.29 |
Daily Change: | 9.74 10.19 |
Daily Volume: | 3,466,961 |
Market Cap: | US$12.870B |
May 09, 2024 May 03, 2024 May 01, 2024 April 11, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORESurmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB